Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Kinglet Stories

2014-02-27 16:28:10

- Achieved All Goals on 'Road to the Clinic'; Launched 'Clinical Map Initiative'- LA JOLLA, Calif., Feb. 27, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today provided an update on its corporate strategy and reported financial results for the fourth quarter and year ended December 31, 2013, including a summary of recent corporate highlights. Corporate Strategy...

2013-08-13 16:26:17

-'Road to the Clinic' Strategy On Track; Preparing for Clinical Development of RG-101 for HCV; Second microRNA Clinical Candidate to be Nominated by Year End - LA JOLLA, Calif., Aug. 13, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended June 30, 2013 and provided a summary of recent corporate highlights. "The second...

2013-08-06 16:28:39

LA JOLLA, Calif., Aug. 6, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended June 30, 2013 on Tuesday, August 13, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Tuesday, August 13, 2013 at 5:00 pm Eastern Daylight Time to...

2013-07-23 08:30:40

LA JOLLA, Calif., July 23, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the completion of an underwritten public offering of 5,175,000 shares of common stock, including 675,000 shares sold pursuant to the full exercise of an option to purchase additional shares previously granted to the underwriters, at a price to the public of $9.50 per...

2013-07-17 08:26:03

LA JOLLA, Calif., July 17, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today the pricing of a public offering of 4,500,000 shares of its common stock at a price of $9.50 per share. The gross proceeds to Regulus from this offering are expected to be approximately $42.8 million, before deducting underwriting discounts and commissions and estimated...

2013-05-07 16:29:08

LA JOLLA, Calif., May 7, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it will report financial results and highlights for the quarter ended March 31, 2013 on Tuesday, May 14, 2013, after the U.S. financial markets close. Regulus will host a conference call and webcast on Tuesday, May 14, 2013 at 5:00 pm Eastern Daylight Time to discuss its...

2013-04-24 16:25:53

LA JOLLA, Calif., April 24, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Kleanthis G. Xanthopoulos, Ph.D., President and Chief Executive Officer, will present a company overview at the 12(th) Annual Needham Healthcare Conference on Wednesday, May 1, 2013 at 12:10 pm EDT. The conference is being held at the Westin Grand Central Hotel in New...

2013-03-28 16:24:47

LA JOLLA, Calif., March 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the 20(th) Annual Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 10:30 am EDT. The conference is being held at the...

2013-02-26 16:27:26

LA JOLLA, Calif., Feb. 26, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Cowen and Company 33rd Annual Healthcare Conference on Tuesday, March 5, 2013 at 8:40 am EST. The conference is being held at the Boston Marriott...

2013-02-20 16:25:55

LA JOLLA, Calif., Feb. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported its financial results for the fourth quarter and year-ended December 31, 2012 and recent company highlights. "In 2012, we successfully achieved significant strategic and financial objectives that have enabled Regulus to become a publicly-traded biopharmaceutical company. In...


Latest Kinglet Reference Libraries

34_aab8b4b6fde8643e28688c6c276bfb73
2005-06-09 12:16:43

The Golden-crowned Kinglet (Regulus satrapa) is a very small songbird characterized by their olive-grey upperparts, white underparts, thin bill and short tail. They have white wing bars, a black stripe through the eyes and a yellow crown surrounded by black. The adult male has an orange patch in the middle of the yellow crown. Their breeding habitat is coniferous forests across Canada, the northeastern and western United States, Mexico and Central America. They build their nests in...

More Articles (1 articles) »